CACSurv reformulates survival modeling as mini-cohort comparative reasoning, where an LLM predicts relative prognostic orderings and introduces concordance-aligned rewards derived from comparable relations under right censoring, enabling censored outcomes to provide ranking supervision without exact event-time targets.
Abstract
Cancer survival prediction supports treatment planning, risk stratification, and follow-up management. Existing methods use structured clinical variables, whole-slide images, genomic profiles, or multimodal inputs, while patient reports remain underexplored. We study report-centric survival prediction using reports that organize pathological, clinical, and molecular evidence. Large language models (LLMs) can reason over such reports, but case-wise time regression introduces two mismatches. First, a formulation mismatch arises because survival evaluation depends on ordering comparable patients, whereas independent time predictions do not enforce ranking consistency. Second, a supervision mismatch arises because a censored patient's observed time indicates survival beyond that point and cannot serve as an exact regression target, although it still implies orderings relative to patients who died earlier. To address these mismatches, we propose CACSurv, a Concordance-Aligned Comparative framework for report-centric survival prediction. CACSurv reformulates survival modeling as mini-cohort comparative reasoning, where an LLM predicts relative prognostic orderings. We introduce concordance-aligned rewards derived from comparable relations under right censoring, enabling censored outcomes to provide ranking supervision without exact event-time targets. At inference, Monte Carlo Reference Aggregation compares each patient with sampled references and aggregates positions into a cohort-level ranking. We establish TCGA-SurvReport, a benchmark covering six TCGA cancer cohorts. CACSurv achieves the highest C-index on all six cohorts and an average C-index of 0.722, outperforming the strongest published survival model by 6.5 percentage points and the strongest LLM time-regression baseline by 4.2 percentage points. Our code, models, and dataset will be available at https://github.com/xmed-lab/CACSurv.
A multi-tier, explainable AI framework designed to risk-stratify patients and predict overall survival using clinical and genomic covariates is developed and demonstrates that explainable machine learning models can robustly predict survivability and highlight actionable features for oncology dashboards.
Across four external evaluations in colon, renal, lung, and glioblastoma cohorts, MIST improves external C-index over standard fusion baselines in the primary comparisons, which support genomic-guided histology attention as a compact and effective strategy for multimodal oncology outcome prediction.
Muhammet Sami Yavuz, Sabri Mustafa Kahya, Richard R. Chen et al.· 0 citations
Outcome prediction from unstructured EHR notes remains challenging, especially for rare cancers with limited representation in large language model (LLM) pre-training data. We present a dynamic prompting framework that retrieves semantically similar patient examples, constructs tailored few-shot prompts and integrate...
Shreya Anil, B. Srinivas, Bo Liu et al.· npj Digital Medicine· 0 citations
Accurate survival prediction for patients with high-grade glioma is important for prognostic assessment and personalized treatment planning; however, substantial intratumoral heterogeneity, complex multimodal MRI patterns, and limited interpretability challenge existing deep learning approaches. This study aims to deve...
Neeshu Chaudhary, Saurabh Shah, C. Thacker· Journal of Electronics Elect...· 0 citations
This work proposes a multi-modal framework that unifies sheaf hypergraph convolution, concept bottleneck supervision, and EST regularization for interpretable survival prediction from brain MRI, the first work to unify sheaf hypergraph convolution, concept bottleneck supervision, and EST regularization.
Mushahid Intesum· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.